VELO.CO : Summary for Veloxis Pharmaceuticals A/S - Yahoo Finance

U.S. Markets open in 4 hrs 11 mins

Veloxis Pharmaceuticals A/S (VELO.CO)


Copenhagen - Copenhagen Delayed Price. Currency in DKK
Add to watchlist
1.11+0.01 (+0.91%)
As of 5:18 AM EST. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.10
Open1.11
Bid1.10 x
Ask1.11 x
Day's Range1.10 - 1.12
52 Week Range0.93 - 2.10
Volume117,401
Avg. Volume1,040,399
Market Cap1.89B
BetaN/A
PE Ratio (TTM)-55.50
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswirelast year

    Veloxis Announces Change In Management

    "Bill has been instrumental in bringing the company successfully through its development phase with regulatory approval of Envarsus® in both Europe and the US and we thank him for his dedicated contribution," said Mette Kirstine Agger, Chairman of the Board of Veloxis. Earlier this week, Veloxis announced the launch of Envarsus XR in the US and is transitioning from a development company into a commercial company. Dr. Polvino will be followed by Craig A. Collard who will take over the position as President and CEO with immediate effect.

  • PR Newswirelast year

    Veloxis Launches Envarsus®XR for Treatment of Kidney Transplant Patients in U.S.

    HORSHOLM, Denmark, Dec. 7, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the U.S. launch of Envarsus ® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection ...

  • We're sorry this is all we were able to find about this topic.